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Abstract
Little is known about procalcitonin (PCT) levels in patients with community-acquired pneumonia (CAP) caused by Legionella pneumophila.
The aim of the present study was to investigate this infection marker in patients admitted with L. pneumophila pneumonia in relation to
conventional inﬂammatory parameters, severity of pneumonia upon admission and clinical outcome. Eighteen patients admitted with CAP
caused by L. pneumophila serogroup 1 were retrospectively examined. PCT measurements were carried out during the ﬁrst week of admis-
sion in addition to measurements of C-reactive protein (CRP), white blood cell (WBC) count and registration of severity of pneumonia
upon admission (CURB-65 score). The mean PCT level upon admission in patients with L. pneumophila pneumonia was 13.5 ng/mL (range
0.3–55.7 ng/mL). Mean CRP level was 397 mg/L (range 167–595 mg/L) and mean WBC count 11.7 · 109/L (range 4.5–20.4 · 109/L). Initial
high PCT levels were indicative of more severe disease as reﬂected by prolonged intensive care unit (ICU) stay and/or in-hospital death.
Patients admitted to the ICU showed signiﬁcantly higher PCT levels compared with the remaining patients [26.7 ng/mL (range 4.6–55.7 ng/
mL) vs. 6.9 ng/mL (range 0.3–29.3 ng/mL); p 0.019]. There was a signiﬁcant correlation between Acute Physiology and Chronic Health
Evaluation-II scores upon ICU admission and initial PCT levels upon hospital admission (r = 0.86; p 0.027). Persistently increased PCT levels
during treatment were indicative of unfavourable clinical outcome. Conventional inﬂammatory parameters (CRP and WBC) and the
CURB-65 score lacked this discriminatory capacity in our study population. PCT may therefore be a valuable tool in the initial clinical
assessment and follow-up of patients with L. pneumophila pneumonia.
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Introduction
Legionella pneumophila serogroup 1 is the second aetiological
cause (following Streptococcus pneumoniae) in patients with
community-acquired pneumonia (CAP) admitted to the
Intensive Care Unit (ICU) [1–5]. To obtain an accurate diag-
nosis, culture, serological investigation and urinary antigen
testing should all be performed in patients suspected of legi-
onellosis [4]. Although introduction of the Legionella urinary
antigen test has improved timely administration of appropri-
ate antibiotic therapy, the clinical course of L. pneumophila
infection is still unpredictable.
Several clinical prediction rules have been constructed to
assess objectively the severity of illness for patients with
CAP [6–8]. Recent guidelines advocate the use of either the
CURB-65 or the Pneumonia Severity Index (PSI). The
CURB-65 criteria (confusion, uraemia, respiratory rate, low
blood pressure, age) generate a severity-of-illness score,
whereas PSI is a more prognostic score system [8,9].
Despite implementation of these clinical prediction rules, the
search continues for additional and reliable prognostic mark-
ers capable of rapidly distinguishing both favourable and unfa-
vourable outcomes of CAP.
Infection markers such as white blood cell (WBC) count
and C-reactive protein (CRP) levels are traditionally used in
the evaluation of pulmonary infections. Procalcitonin (PCT), a
12.6-kDa 116 amino acid polypeptide, is an infection marker
that rapidly increases in concentration in bacterial infections
but remains low in viral diseases. By the early 1990s, PCT lev-
els had been reported to be related to the onset and severity
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of bacterial infection [10]. Despite some controversy and vari-
ability attributable to the clinical circumstances, PCT seems a
promising biomarker in sepsis and pneumonia [11–19].
In CAP patients, PCT levels can be used to predict devel-
opment of complications and death in high-risk patients or
bacterial aetiology in low-risk patients [20]. PCT levels have
been used to guide antibiotic therapy and showed a higher
prognostic accuracy in comparison with CRP and WBC
count [20–22]. Recently, it has been demonstrated that PCT
levels upon admission predict severity and outcome in
patients with CAP [23]. In critically ill patients, high maxi-
mum PCT levels and a PCT increase over 1 day have been
shown to be early independent predictors of all-cause mor-
tality after ICU admission. Unlike PCT, CRP levels or WBC
count did not predict survival and outcome in these patients
[24].
Until recently, little was known about PCT levels in
patients with CAP due to L. pneumophila. Jereb et al. showed
that PCT levels upon admission allow discrimination between
‘typical’ and ‘atypical’ CAP, with low PCT levels in patients
with atypical and high PCT levels in patients with typical
pneumonia. However, the PCT level in the only legionellosis
patient included in the study was the highest in the atypical
pneumonia group and was well above the median PCT level
in the typical pneumonia group, warranting further studies
[25]. Prat et al. [26] showed moderately elevated PCT levels
upon admission in 21 patients with L. pneumophila serogroup
1 pneumonia. Analysing patients with Legionella pneumonia,
Franzin et al. recorded high PCT levels in early sera samples
(taken 1–7 days after onset of symptoms), which decreased
progressively with time. Patients who did not survive had sig-
niﬁcantly higher PCT levels compared with those who did
survive [27].
To explore further the value of PCT in legionellosis, we
investigated the relationships between PCT levels and tradi-
tional infection markers (CRP level and WBC count), a clini-
cal prediction rule (CURB-65) and clinical course and




Sera and patient records from adult patients admitted over a
3-year period (2005–2007) with CAP caused by L. pneumophil-
a serogroup 1 were examined. Patients had been admitted
to the Jeroen Bosch Hospital, an 800-bed teaching hospital in
‘s-Hertogenbosch, the Netherlands. Approximately 180
patients with CAP are admitted annually to this hospital.
Individual patient consent was not obtained since sera
used in this study were all drawn for routine clinical chemical
or serological analysis at the request of the treating physi-
cian; the Internal Review Board of the Jeroen Bosch Hospital
approves the anonymous use of discarded blood for scientiﬁc
purposes. All patients who donate blood are informed of this
possibility and have the right of refusal.
Diagnosis and treatment
The case deﬁnition proposed by the European Working
Group for Legionella infections for conﬁrmed cases was used
in this study [28]. Diagnosis was made using the Legionella
urinary antigen test for detection of L. pneumophila sero-
group 1 antigen (Binax, Portland, ME, USA). Other concomi-
tant causes of bacterial infection, present upon admission or
acquired during the study period, and possibly explaining per-
sistently elevated PCT levels, were excluded. Antibiotic
treatment of patients was consistent with national guidelines
and consisted of second- or fourth-generation ﬂuoroquinol-
ones [29]. Timely adequate antibiotic treatment (within 12 h
of admission) was achieved in 14/18 (78%) patients [30].
Infection markers
PCT levels were measured using a commercially available
sensitive immunoluminometric assay (LIA sensitive) (Brahms
AG, Henningsdorf, Germany). The assay involves a two-step
LIA using a coated tube system (sandwich principle). The val-
idated sample matrix for this assay is serum or plasma. The
commercially available sensitive LIA that was used in this
investigation has a measuring range of 0.01–20 ng/mL. The
functional assay sensitivity is 0.05 ng/mL according to the
manufacturer’s speciﬁcations. The assay is free of high-dose
hook effects up to concentrations of 185 ng/mL. The interas-
say precision in the clinically relevant range is <10% CV. All
samples were retrospectively determined at the Department
of Clinical Chemistry & Haematology of the Jeroen Bosch
Hospital. Samples with PCT levels >20 ng/mL were diluted
with isotonic saline and measured again. PCT levels <0.5 ng/
mL were considered normal.
CRP levels were measured with a fully automated
enzyme-linked immuno-assay using an Aeroset 2.0 analyser
(Abbott Diagnostics, Santa Clara, CA, USA). WBC counts
were determined on a Sysmex XE-2100 haematology analy-
ser (Sysmex Corporation, Kobe, Japan).
Clinical prediction rule
The CURB-65 score was used as a clinical prediction rule.
This score is based upon ﬁve easily measurable factors from
which its name is derived: confusion (based upon a speciﬁc
mental test or new disorientation to person, place, or time),
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urea (blood urea nitrogen) >7 mmol/L (20 mg/dL), respira-
tory rate ‡30 breaths/min, blood pressure (systolic
<90 mmHg or diastolic £60 mmHg) and age ‡65 years. The
CURB-65 score is routinely used in our hospital for patients
admitted with CAP and documented in the patient records.
In patients admitted to the ICU, the severity of disease was
predicted using the Acute Physiology and Chronic Health
Evaluation (APACHE)-II score system [31]. Unfavourable
clinical outcome was deﬁned as prolonged ICU stay
(>14 days) and/or in-hospital death.
Statistical analysis
Statistical analysis was performed using SPSS 15 (SPSS Inc.,
Chicago, IL, USA). Analysis of descriptive variables was per-
formed in all cases. The association between biomarkers
(PCT, CRP, WBC count), the CURB-65 score and ICU
admission was evaluated using non-parametric tests (Mann–
Whitney U). Correlation between PCT, CRP and the
APACHE-II score was calculated using Pearson correlation




A total of 24 patients with pneumonia due to L. pneumophila
serogroup 1 were admitted to the hospital during the study
period. Six patients could not be included because acute-
phase serum samples were not recovered. Thus, the study
population consisted of 18 patients with a mean age of
54 years (range 28–93). The mean hospital stay for all
patients was 14 days (range 3–91). Baseline characteristics
are shown in Table 1.
Severity of illness
The mean CURB-65 score of all patients was 2 (range 0–5).
Six patients were admitted to the ICU. The mean CURB-65
score in this group was 3 (range 1–4) and mean ICU stay
15 days (range 3–45). The differences in CURB-65 score
between patients admitted to the general ward and those
admitted to the ICU showed a trend towards statistical sig-
niﬁcance (p 0.065).
The mean APACHE-II score upon ICU admission was 26
points (range 11–35). Four patients developed multiple organ
failure leading to a prolonged ICU stay of 45 days in one
case and death in two cases because of unresponsiveness to
treatment. Multiple organ failure was characterized by severe
circulatory and respiratory failure, diffuse intravascular coag-
ulation and, in three patients, renal failure requiring renal
replacement therapy. Two patients were admitted to the
ICU because of respiratory insufﬁciency. One patient made a
swift recovery. The other patient was intubated due to con-
comitant acute cardiac failure requiring mechanical ventila-
tion for only 1 day. Both patients were discharged from the
ICU within 72 h. Characteristics of patients admitted to the
ICU are shown in Table 2.
PCT levels, CRP levels and WBC counts
The mean PCT level upon hospital admission was 13.5 ng/mL
(range 0.3–55.7). Patients admitted to the ICU showed signif-
icantly (p 0.019) higher PCT levels upon hospital admission
compared with the remaining patients [26.7 ng/mL (range
4.6–55.7) vs. 6.9 ng/mL (range 0.3–29.3)]. There was a signiﬁ-
cant correlation (r = 0.86; p 0.027) between APACHE-II
scores upon ICU admission and initial PCT levels upon hos-
pital admission. Overall, survivors had signiﬁcantly (p 0.025)
lower PCT levels upon hospital admission compared with
non-survivors [9.1 ng/mL (range 0.3–29.3) vs. 48.7 ng/mL
TABLE 1. Baseline characteristics of the study patients
No. Age Sex PCT CRP WBC CURB-65 ICU LOS Survival
1 28 F 10.3 347 7.4 2 Yes 9 Yes
2 54 M 4.7 375 12.7 0 No 9 Yes
3 68 M 4.2 455 9.8 2 No 13 Yes
4 58 M 1.4 287 12.9 2 No 7 Yes
5 31 M 5.5 390 20.4 0 No 6 Yes
6 67 M 1.1 370 10.0 2 No 5 Yes
7 93 F 5.1 420 12.7 5 No 13 Yes
8 55 M 0.5 347 14.0 0 No 5 Yes
9 49 F 4.6 284 17.5 1 Yes 13 Yes
10 62 F 55.7 562 8.6 2 Yes 4 No
11 55 M 18.3 595 9.7 3 Yes 20 Yes
12 54 M 41.7 291 6.5 4 Yes 25 No
13 50 M 0.3 298 13.9 0 No 3 Yes
14 52 F 21.6 521 4.5 2 No 9 Yes
15 35 F 8.2 499 10.4 1 No 7 Yes
16 51 M 29.3 351 10.3 2 No 12 Yes
17 50 M 0.5 167 10.6 1 No 6 Yes
18 61 M 29.3 586 18.5 3 Yes 91 Yes
Mean 54 13.5 397 11.7 2 14
PCT, procalcitonin (ng/mL); CRP, C-reactive protein (mg/L); WBC, white blood
cell count (109/L); ICU, Intensive Care Unit admission; LOS, length of stay
(days); F, female; M, male.
TABLE 2. Characteristics of patients admitted to the
Intensive Care Unit
No. PCT APACHE CURB-65 ICU Survival Description
1 10.3 24 2 3 Yes RI
9 4.6 11 1 3 Yes RI
10 55.7 35 2 4 No MOF
11 18.3 24 3 8 Yes MOF
12 41.7 30 4 25 No MOF
18 29.3 32 3 45 Yes MOF
Mean 26.7 26 3 15
PCT, procalcitonin (ng/mL); APACHE, Acute Physiology and Chronic Health
Evaluation-II score; ICU, length of stay during Intensive Care Unit admission
(days); RI, respiratory insufﬁciency; MOF, multiple organ failure including respira-
tory insufﬁciency requiring mechanical ventilation.
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(range 41.7–55.7)]. Upon hospital admission, the mean CRP
level was 397 mg/L (range 167–595) and the mean WBC
count 11.7 · 109/L (range 4.5–20.4). There was no signiﬁcant
difference between CRP and WBC count upon hospital
admission in patients admitted to the ICU vs. admission to
the general ward, or in survivors vs. non-survivors. Likewise,
there was no signiﬁcant correlation between APACHE-II
scores upon ICU admission and initial CRP levels and WBC
counts upon hospital admission. PCT and CRP levels and
WBC count upon hospital admission for all patients are
shown in Table 1.
PCT and CRP kinetics
PCT and CRP kinetics in 15 patients during the ﬁrst week of
hospital admission are shown in Figs 1 and 2, respectively. In
three patients, only an admission day serum sample was
available; therefore kinetics could not be studied. CRP levels
were high upon hospital admission in all patients and levels
decreased during treatment regardless of whether there was
a favourable or unfavourable clinical outcome. The kinetics
of PCT levels showed a different pattern. In most patients,
PCT levels were elevated upon hospital admission and
decreased during treatment.
However, in the three patients with an unfavourable clini-
cal outcome, PCT levels remained clearly elevated while
CRP levels decreased. Based on the literature [32–34], we
consider renal failure in these patients unlikely as the cause
of the persistently elevated PCT levels. None of the patients
developed nosocomial infections during the ﬁrst week fol-
lowing hospital admission that could have explained the per-
sistently elevated PCT levels. One of these three patients
was among the group of four patients that had not received
appropriate antibiotic therapy within 12 h after hospital
admission, but our study does not allow a conclusion regard-




















FIG. 1. Procalcitonin kinetics in patients with
Legionella pneumophila pneumonia during the
ﬁrst week after admission (n = 15). Solid lines
correspond to procalcitonin kinetics in patients
admitted to the Intensive Care Unit and
interrupted lines to procalcitonin kinetics in
























†d25 FIG. 2. C-reactive protein kinetics in patients
with Legionella pneumophila pneumonia during
the ﬁrst week after admission (n = 15). Solid
lines correspond to C-reactive protein kinetics
in patients admitted to the Intensive Care Unit
and interrupted lines to C-reactive protein
kinetics in patients admitted to the regular
ward. Adm = time of admission.
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Discussion
Introduction of the Legionella urinary antigen test has allowed
for timely diagnosis of patients with L. pneumophila pneumo-
nia and results can now be obtained in an emergency depart-
ment setting. Determination of PCT levels in these patients
is useful both upon admission and during treatment. High
PCT levels upon hospital admission indicate a potential need
for intensive care treatment and persistently elevated PCT
levels are associated with poor outcome.
It has been shown previously that PCT is more accurate
in diagnosing bacterial infections than other routinely used
infection markers [12,15,24,35]. The use of PCT in determin-
ing treatment options has also been studied recently and has
shown promising results. Prat et al. showed that there is a
signiﬁcant correlation between elevated PCT levels and the
severity of the pneumonia as scored by the PSI. Patients in
the high-risk classes (IV and V) had signiﬁcantly higher PCT
levels [6,26]. In the recent CAPNETZ study (German Com-
petence Network for the study of CAP), it was shown that
PCT had at least as good a prognostic value as a clinically
validated severity score [23]. It has been shown previously
that elevated PCT levels in severe cases of CAP are a mar-
ker of poor prognosis and an independent risk factor of
mortality, whereas a decrease in PCT levels predicted sur-
vival [17]. Elevated upon PCT levels on admission are
strongly associated with severity of disease as measured by
the APACHE-II score, and serum PCT levels increase signiﬁ-
cantly with the severity of sepsis in ICU patients admitted
for severe CAP [11,16].
Few studies have been performed evaluating PCT mea-
surements in patients with speciﬁc bacterial infections, in
particular L. pneumophila pneumonia. In our study, patients
admitted to the hospital with L. pneumophila pneumonia
showed PCT levels ranging from 0.3 to 55.7 ng/mL (mean
13.5 ng/mL). Patients requiring ICU treatment showed signif-
icantly higher PCT levels upon hospital admission. APACHE-
II scores upon ICU admission correlated well with initial
PCT levels upon hospital admission. In this context it has
been shown previously that APACHE II scores >15 upon
admission and serum Na levels £136 are independent prog-
nostic factors related to death in legionellosis (in our study
these factors were both present in 5/6 ICU admitted
patients) [3].
According to longitudinal analysis, unfavourable clinical
outcome seemed to be related to persistently increased
PCT levels. This discriminatory capacity was not seen with
the CURB-65 score, WBC count or CRP level. The latter
were markedly increased upon hospital admission and
decreased in all patients during the ﬁrst week regardless of
clinical stagnation in patients. Thus, our results are in line
with recent studies showing the promising discriminatory
and prognostic capacity of PCT level determination in
patients with CAP [11,16,17,20,23,27]. A very recent retro-
spective study has shown similar results predicting a less
favourable outcome for patients with L. pneumophilia pneu-
monia in case of increased initial PCT concentrations [36].
Although the retrospective design with a relatively small
sample of patients might limit generalization of the results,
we believe that our results may be of value in assessment
and follow-up of patients with L. pneumophila pneumonia.
Therefore, a prospective observational cohort study of PCT
and other infection markers in patients with L. pneumophila
pneumonia is warranted.
Legionella pneumophila pneumonia can present with a vari-
ety of respiratory signs ranging from mild disease to severe
respiratory insufﬁciency and accompanying organ failure
requiring intensive care treatment. Measurement of PCT
levels, in conjunction with clinical judgement and clinical pre-
diction rules, may offer an additional tool in both the initial
assessment and follow-up of treatment in patients with
L. pneumophila pneumonia.
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